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Abstract: The development of psoriasis and psoriatic arthritis is a multistep process that leads 
to chronic or recurrent inflammation. Recent studies have suggested the importance of T helper 
(TH)1 and TH17 cells, accessory cells, and proinflammatory cytokines in the pathogenesis of 
the enthesis, synovium, and skin involvement in psoriasis in the presence of susceptibility genes 
that remain quiescent until triggered. Biologics, such as soluble CTLA-4 immunoglobulin, tumor 
necrosis factor (TNF) inhibitors, and ustekinumab, inhibit T cell activation which eventually 
leads to further stimulation of the interleukin 12, 17, and 23 axis, TNF-α, and lymphotoxin-α. 
Treatment with TNF-α blockers has been effective in refractory psoriasis and psoriatic arthritis, 
but there is still a subgroup of patients who do not respond to TNF inhibitors and,   paradoxically, 
when treated, may develop TNF-induced psoriasis. Ustekinumab, because of its different 
mechanism of action at the level of the interleukin 12, 17, and 23 pathways, is an alternative 
treatment for this group of patients.
Keywords: psoriasis, psoriatic arthritis, biologics, ustekinumab, tumor necrosis factor 
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Introduction
Psoriasis is a relatively common chronic inflammatory disease that affects around 
3% of the general population, and is characterized by an exaggerated proliferation 
of keratinocytes secondary to an activated immune system. It has a predilection for 
Caucasians, with an estimated prevalence of 0.2%–3.0% in the general population. The 
incidence is highest at the age of 20–39 years in males and 40–59 years in females, 
with an equal male-to-female ratio.1
Psoriasis clinically manifests as raised, well defined erythematous plaques with 
irregular borders and silvery scales, affecting the upper and lower extremities equally, 
but with a predilection for the elbows, knees, scalp, and trunk. Psoriasis vulgaris or 
plaque psoriasis accounts for almost 90% of the dermatological presentation of the 
disease, but several other forms, including guttate, inverse, erythrodermal, pustular, 
and palmoplantar psoriasis may occur, as well as nail involvement. Psoriasis may have 
significant systemic involvement, which is underscored by the coexistence of various 
clinical disorders, including eye, cardiovascular, and intestinal problems, metabolic 
syndrome, and joint inflammation. It has a very high negative impact on quality of life, 
requires long-term treatment which usually has a high social and economic impact, 
and is also associated with a decreased life span.2,3
Our understanding of the pathogenetic events leading to psoriasis has improved 
significantly in recent years. It is well established that an interplay of environmental, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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genetic, and immunological mechanisms is associated with 
development of the disease, and this has also led to the 
  development of biologics resulting in significant advances 
in the management of severe or refractory forms of the 
disease.4–6 Three classes of biologics have been introduced, 
including T cell inhibitors, tumor necrosis factor (TNF)-α 
inhibitors, and most recently, ustekinumab, a biologic that 
targets the p40 subunit common to interleukins 12 and 23.7
This review focuses on the effectiveness of biological 
therapy, particularly ustekinumab, in the treatment of pso-
riasis, and attempts to provide a comparative assessment of 
the different classes of biologics available for the treatment 
of psoriasis. In order to accomplish this, we have used the 
Psoriasis Area and Severity Index 75 (75% response) score 
to compare the efficacy of current biologics. A recently 
published systematic review that analyzed all of the di  fferent 
clinical severity scores used for psoriasis concluded that 
the Psoriasis Area and Severity Index score has been the 
instrument used the most extensively and is now thoroughly 
validated.8
Pathophysiology
Genetic studies have clearly demonstrated that the incidence 
of psoriasis is higher among first- and second-degree rela-
tives of patients with psoriasis than in the general population 
and, to date, nine chromosomal loci have been recognized as 
having a high predisposition for psoriasis. These are classified 
as susceptibility genes PSORS1 through to PSORS9, with 
PSORS1 being the most prevalent and accounting for almost 
50% of heritability.9,10 PSORS2, PSORS3, and PSORS4 are 
also associated with loci of susceptibility for metabolic 
syndrome, type 2 diabetes, familial hyperlipidemia, and 
cardiovascular disease. Genome-wide association studies 
have also identified several new genomic loci, and compelling 
evidence has shown an interaction between the HLA-C and 
ERAP 1 loci, implicating pathways that integrate epidermal 
barrier dysfunction with innate and adaptive immune dys-
regulation in psoriasis.11 CDKAL1 is also associated with 
type 2 diabetes genes with known function in cardiovascular 
risk, such as the ApoE4 isoform of apoprotein E, which is 
significantly more prevalent in patients with chronic plaque 
and guttate psoriasis than in controls.
A great body of evidence has accumulated in support of an 
important role for dysregulation of the immune system in the 
development of skin involvement in psoriasis, especially in 
the interplay between cells of the innate and adaptive immune 
systems and their inflammatory mediators in the skin epithe-
lium and connective tissue (see Figure 1). It is still a matter 
of debate whether the epidermis, dermis, or a combination 
of both sites is primarily affected. One of the dysregulated 
immune mechanisms in psoriasis involves plasmacytoid 
dendritic cells and their high production of type I interferon 
(IFN)-α signal, which has been shown to be present in early 
skin lesions of psoriatic patients.12,13 Plasmacytoid dendritic 
cells are activated through complexes of antimicrobial 
  peptides LL-37 cathelicidin and DNA in a toll-like receptor-
9-dependent manner, which may explain how immunological 
tolerance is disrupted in patients with psoriasis.14
More recently, increasing attention has been focused on 
keratinocytes, and substantial evidence suggests that these 
cells are a direct target for a specific set of cytokines, leading 
to regulation of their biological properties, such as secretion 
of cytokines, chemokines, and antimicrobial peptides, and 
their differentiation and migration capacities.15
Psoriasis is now considered the paradigm of an inflam-
matory disease involving the proinflammatory T helper 
(Th)17 subset.16,17 In vitro studies have characterized certain 
cytokines as being able to induce specific expression patterns 
related to the innate immune response, such as interleukin 
1a, TNF-α, interleukin 17a, and oncostatin M, and may be 
able to induce skin inflammation reminiscent of psoriasis in 
animal models.18
Guilloteau et al identified an optimal and relevant cytokine 
combination able to synergize in vitro in order to generate an 
inflammatory keratinocyte model capturing some features of 
lesional psoriatic skin.19 In vitro and in vivo analyses were 
performed using normal and psoriatic skin samples, keratino-
cyte cell cultures, and murine models of skin inflammation. 
Following screening of 36 different cytokines, interleukins 
1a, 1b, 6, 17a, 22, and 24, oncostatin M, and TNF-α were 
identified as being able to modify the expression of at least 
five genes. Among these, interleukins 1a, 17a, and 22, as well 
as oncostatin M and TNF-α, showed the strongest   synergistic 
activity in the production of B defensin and CXCL8. 
I  nterleukin 17a and TNF-α were shown to be more crucial 
to the activity of this combination. It was concluded that the 
synergistic ac  tivity of several cytokines on keratinocytes is 
implicated in the pathogenesis of the disease.20
Psoriatic skin and synovial fluid from patients with psoriatic 
arthritis are rich in various cytokines, including interleukins 6, 
17, and 23, as well as RORγt (necessary for the induction of 
interleukin 1R1 and 23R receptor expression), which eventually 
mediates the activation of nuclear factor κB and Stat signaling 
for further Th17 differentiation and lineage commitment.21 
The pathogenetic role of Th17 cells is further supported by 
the increased concentrations of the p40 subunit of interleukins Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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12, 23, and 17 that are overexpressed in the affected skin and 
psoriatic joints.22,23 Many of the molecules involved in the 
immunological response are targeted by the newer biologics, 
including ustekinumab, and are the focus of this discussion.
Treatment
Conventional treatment includes topical agents, photother-
apy, and/or systemic immunosuppressive agents. However, 
therapy for moderate to severe or refractory psoriasis has been 
revolutionized with the introduction of biologics in the past 
7–10 years.24–27 The first US Food and Drug Administration 
(FDA) biologic approved for plaque psoriasis was alefacept 
in January 2003, and this was followed by six other agents, ie, 
efalizumab in October 2003, infliximab in September 2006, 
etanercept and adalimumab, and most recently, ustekinumab, 
approved in September 200928 (Table 1).
The overall efficacy and safety profile of biological 
therapy is well established. However, long-term safety 
data are lacking, and caution with its use should be taken 
into consideration due to an increase risk of opportunis-
tic infections, worsening of heart failure, development of 
neurologic disease, and malignancy. Efalizumab was vol-
untarily withdrawn from the market in June 2009, due to a 
potential risk of patients developing progressive multifocal 
leukoencephalopathy.29
Alefacept
Alefacept was the first biologic introduced for the treatment 
of moderate to severe psoriasis. Alefacept is a human fusion 
protein of the CD2-binding region of leukocyte function-
associated antigen-3 and the CH2 and CH3 domains of 
immunoglobulin G, and acts to inhibit T cell activation and 
induces apoptosis of memory T cells.25
The first relevant clinical trials used alefacept as mono-
therapy for chronic plaque psoriasis. Ellis et al conducted 
a multicenter, randomized, controlled Phase II trial of 229 
Th1/Th17/Treg : IL-1β, IL-2, IL-6, 
IL-10, IL-15, type I/II IFNs, TNF-α,
microbial peptides
PDC/neutrophils/keratinocytes: 
IFN-α, IL-12/17/23/26, Growth factors, CC,
transcription factors, (RORγt)
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Figure 1 Pathophysiology of psoriasis.
Abbreviations: PDC, plasmacytoid dendritic cells; MDC, myeloid dendritic cells; NKC, natural killer cells; Th1 and Th17, Type 1 and 17 helper T cells; Treg, regulatory 
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patients who received one of three doses of intravenous 
alefacept (0.025 mg, 0.075 mg, or 0.150 mg/kg) or placebo 
for 12 weeks, with a 12-week follow-up. The PASI 75 score 
improved by 38% to 53% in the alefacept group compared 
with 21% in the placebo group. Long-term follow-up 
in these groups of patients showed a sustained response 
for up to 10 months, some even up to 18 months before 
retreatment.25,30
Phase III clinical trials have shown similar results 
regarding alefacept. Menter et al determined the efficacy 
of multiple courses of alefacept in patients who failed to 
achieve a .50% reduction in PASI after their first course of 
treatment. They demonstrated that multiple-course therapy 
in these patients had almost a double increase in achieving 
PASI 75 scores, from 29% to 54% in patients receiving one 
course compared with five courses of treatment.31
Two other randomized, double-blind, placebo-controlled 
Phase III studies were performed to evaluate the efficacy 
and tolerability of alefacept in patients with chronic plaque 
psoriasis. Alefacept administered intravenously or intra-
muscularly was shown to be effective and well tolerated for 
chronic plaque psoriasis.32,33 Additionally, a multicenter, 
observational Phase IV Canadian study of psoriasis patients 
treated with alefacept, known as AWARE (Amevive® 
  Wisdom Acquired from Real-world Evidence), was per-
formed. The main goals of AWARE were to develop a shared, 
real-time, national clinical database to support best practice 
and optimize the care of patients receiving alefacept and to 
gain an understanding of how alefacept is used in Canadian 
clinical practice. All patients in the AWARE patient popu-
lation were receiving one or more treatments for psoriasis 
prior to or at baseline, and the majority continued to receive 
concomitant treatment at the time of study enrollment. It 
was concluded that alefacept was commonly added to other 
antipsoriatic therapies in Canada, and may allow for dosage 
reduction or discontinuation of concomitant systemic agents 
or phototherapy.34,35
Several studies have shown that alefacept is the least 
commonly prescribed biological therapy for psoriasis, but 
is a safe and well tolerated drug, with fatigue and arthralgia 
as the main adverse reactions, and an incidence of around 
20%.36,37
However, as with most new emerging therapeutic agents, 
cost has become an important factor regarding treatment of 
patients. In a recent study, Beyer and Wolverton analyzed 
the total cost of systemic psoriasis therapies, concluding that 
the total cost of alefacept administered as two 12-week courses 
was around US $30,000 compared with an approximate cost 
of US $1000 for methotrexate.38
TNF inhibitors
Anti-TNF-α agents were the next class of biologics to be 
approved by the FDA for the treatment of moderate to 
severe chronic plaque psoriasis, with infliximab being the 
first approved. Its potential beneficial use for the treatment 
of psoriasis was recognized following the observation of 
elevated levels of anti-TNF in both skin and serum, which 
have a positive correlation with disease activity scores and 
a significant reduction after successful treatment.39
Infliximab
Infliximab is a chimeric monoclonal antibody formed from 
murine and human DNA sequences by binding a mouse 
variable region and a human IgG1-α constant region. It has 
the ability to bind to both forms of TNF, and transmembrane 
and soluble receptors, thus achieving complete blockade 
of TNF-α.27,28 At a dosage of 5 mg/kg over 2–3 hours at 
baseline, at weeks 2 and 6, and every eight weeks thereafter, 
i  nfliximab showed an average 80% response on PASI scores. 
In the pivotal clinical trials, 80% of patients achieved a PASI 
Table 1 Biologic agents: general characteristics
Biologic Structure Dosage Efficacy Major
PASI 75 Safety issues
Alefacept Human LFA-3 15 mg: qw for 12 weeks week 14%–33% Lymphopenia
(Amevive®) Fusion protein repeat qw for 12 weeks week 24%–60% (PASi 50)
Infliximab Chimeric monoclonal 5 mg/kg: 0, 2, 6, q8w week 10%–80% infusion reactions
(Remicade®) anti-TNF-α antibody week 24%–82% Opportunistic infections
etanercept Human p75 TNF-receptor 50 mg: biw for 12 weeks week 12%–49% injection site reactions
(enbrel®) Fc fusion protein 50 mg: qw week 24%–54% Opportunistic infections
Adalimumab Human monoclonal 80 mg: loading dose week 16%–71% injection site reactions
(Humira®) anti-TNF-α antibody 40 mg: qow week 24%–70% Opportunistic infections
Ustekinumab Human monoclonal 90 mg: 0, 4, q12w week 12%–66% Opportunistic infections
(Stelara®) anti-p40 antibody week 40%–90%
Abbreviations: biw, twice weekly; LFA, lymphocyte function associated antigen; PASi, psoriasis area and severity index; TNF, tumor necrosis factor.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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75 score at week 10 and 60% achieved a sustained response 
at week 50, with a 90% improvement in the Dermatology 
Life Quality Index.40,41
One of the most remarkable effects of infliximab is the 
rapid response seen, noted even during the first two weeks of 
treatment.42 Nearly half rheumatoid arthritis patients treated 
with infliximab develop anti-infliximab antibodies within 
the first year of treatment, and the concomitant use of other 
immunosuppressive agents, especially methotrexate, could 
prevent new antibody formation.43,44
etanercept
Etanercept is a recombinant human TNF-α receptor (p75) 
  protein fused to the Fc portion of IgG1, that binds not only 
the TNF-soluble and transmembrane portions, but also 
lymphotoxin-α. Similar to other TNF inhibitors, etanercept 
is also approved for the treatment of other autoimmune 
conditions, such as spondyloarthropathies and rheumatoid 
arthritis.28 Etanercept is administered for psoriasis at a dose of 
50 mg su  bcutaneously twice a week for the first 12 weeks and 
thereafter once a week. Efficacy has been reported in many 
pivotal trials, with an average of 50% of patients achieving a 
PASI 75 score at week 12 compared with 4% in the placebo 
groups, and 60% of patients achieving PASI 75 at week 24 after 
continuous treatment.45–47 The presence of nonneutralizing anti-
etanercept antibodies occurs in a small proportion of psoriasis 
patients and is not related to a decreased response to therapy. 
Neutralizing antibodies have not been described to date.48
Adalimumab
Adalimumab is the first fully humanized monoclonal anti-
body against TNF-α. Like infliximab and etanercept, adali-
mumab inhibits both and TNF-soluble and transmembrane 
particles, and also the two surface receptor ligands, p75 
and p55. Adalimumab is administered as a subcutaneous 
  injection with a usual dose for psoriasis patients of 80 mg in 
the first week, 40 mg in the second week, and 40 mg every 
two weeks thereafter in a continuous fashion. In the pivotal 
study of adalimumab for psoriasis, the clinical response 
observed was 70% in patients achieving PASI 75 scores 
at week 15 compared with 7% in patients on placebo.49,50 
Development of antiadalimumab antibodies may occur in 
up to 20% of patients with rheumatoid arthritis, and may 
influence response to treatment.51
Ustekinumab
Ustekinumab is the latest biologic approved by the FDA for 
the treatment of moderate to severe plaque psoriasis. It is a 
human monoclonal antibody generated from transgenic mice 
by genetic engineering techniques. The main target of this 
biologic is the p40 subunit shared by two cytokines, inter-
leukin 12 and 23, thereby preventing its interaction with the 
receptor and thus blocking subsequent signaling, differentia-
tion, and cytokine production.52 Both cytokines are mainly 
produced by activated dendritic cells. Interleukin 12 mainly 
activates Th1 IFN-γ, TNF-α, and cells producing interleukin 
2, whereas interleukin 23 has a main role in the development 
of Th17 and interleukin 22, and cells   producing TNF-α.53
When the drug was designed, the intention was to test 
it in patients with ulcerative colitis, rheumatoid arthritis, 
psoriasis, psoriatic arthritis, and multiple sclerosis, because 
experimental mouse model analyses demonstrated blockade 
of interleukins 12 and 23, with subsequent prevention of 
arthritis and colitis.54
The most important clinical trials of ustekinumab for 
psoriasis are PHOENIX-1 and PHOENIX-2. Both are large-
scale, placebo-controlled Phase III trials designed to evaluate 
the efficacy and safety of the drug in patients with moderate 
to severe plaque psoriasis.55,56
The primary outcome in both studies was the proportion 
of patients achieving $75% improvement in PASI 75 scores 
at week 12 compared with baseline. The secondary outcomes 
included the Physician Global Assessment score of minimal 
or cleared psoriasis at week 12, a change from baseline in the 
Dermatology Life Quality Index at week 12, and in the ran-
domized withdrawal phase, time to loss of PASI 75 response 
in the group receiving maintenance ustekinumab compared 
with the group withdrawn from the drug at week 40. Accord-
ing to the inclusion criteria, patients had to be aged over 
18 years, with a diagnosis of plaque psoriasis for at least six 
months, be candidates for phototherapy or systemic treatment, 
have more than 10% of body surface area involvement, and a 
PASI 75 score $12. Exclusion criteria were mostly the same 
for other studies of biologics, ie, no symptoms of active tuber-
culosis, no recent serious infections, no known malignancy, 
and no recent treatment with biologic or topical agents.
In PHOENIX 1 and PHOENIX 2, 766 and 1230 patients 
with similar baseline characteristics were randomized, 
respectively, with almost two-thirds having been previously 
treated with phototherapy and one-half having been treated 
previously with conventional systemic treatments and/or 
biologics55,56 (Table 2).
In PHOENIX 1, patients were randomized to receive 
ustekinumab 45 mg or 90 mg, or placebo, at weeks 0 and 4 
and then every 12 weeks thereafter. At week 12, patients in 
the placebo group were rerandomized to receive ustekinumab Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
46
Garcia-Valladares et al
45 mg or 90 mg, with a subsequent dose at week 16 and every 
12 weeks thereafter. At week 28, all partial responders (defined 
as PASI score 50–75) were switched to dosing every eight 
weeks and all nonresponders (defined as PASI score ,50) 
had their therapy discontinued, but continued to be   followed 
up. At week 40, all partial responders were switched to dosing 
every eight weeks, and responders (defined as PASI .75) were 
allocated to treatment c  ontinuation or treatment interruption. 
The P  HOENIX 2 study was identical to PHOENIX 1, and all 
patients in both studies were to be followed up for five years.
In both trials, treatment with ustekinumab induced a rapid 
response rate, with a higher proportion of patients achieving 
PASI 50 from baseline by week 2 and PASI 75 by week 4, 
compared with placebo.
Approximately 70% of the patients achieved the primary 
endpoint of PASI 75 at week 12 compared with 3% for the 
placebo group in both trials at the 45 mg dose and an almost 
80% response rate with the 90 mg dose at week 12. The 
highest response rate was achieved at week 24, with a 76% 
response in the 45 mg group and an 85% response in the 
90 mg group. At week 28, more than 90% of patients were 
classified as partial responders and 50% of patients achieved 
a PASI 90 response rate, and efficacy was maintained until 
week 40 with dosing every 12 weeks.
Regarding safety and tolerability, there were no 
  significant adverse events at both doses (45 mg versus 90 mg) 
compared with placebo in either trial, and no anaphylactic 
reactions or serum sickness was observed. Furthermore, 
rates of i  nfections were similar in both groups, with upper 
respiratory tract infections being the most common adverse 
events in approximately 13% in each group.
The only head-to-head comparison of biological therapy 
in patients with psoriasis was the ACCEPT (Efficacy and 
Safety of Ustekinumab Compared to Etanercept in the Treat-
ment of Subjects with Moderate to Severe Plaque Psoriasis) 
trial, which was a comparison of etanercept and ustekinumab 
in 900 patients. In the etanercept group, patients received 
50 mg twice a week for 12 weeks, while two groups of patients 
received ustekinumab 45 mg or 90 mg at weeks 0 and 4.57
The results showed a PASI 75 response of 68% and 
74% for both groups of patients who received ustekinumab, 
compared with a 57% response in the etanercept group at 
week 12, which achieved statistical significance at the levels 
of P = 0.01 and P , 0.001, respectively. The trial showed 
significant improvement in the Physician Global Assessment 
in patients who received ustekinumab compared with those 
on etanercept. Patients who were unresponsive to etanercept 
were switched to ustekinumab, with almost a 50% response 
rate within the first 12 weeks.
This head-to-head comparison clearly showed a 
s  ignificant superiority of ustekinumab over etanercept for 
the treatment of patients with moderate to severe psoriasis. 
The clinical and cost effectiveness of ustekinumab in r  elation 
to other biologics is uncertain. The provisional National 
Table 2 Ustekinumab: Phase iii clinical trials
Phoenix I Primary endpoint
N Dosing Week PASI 75 response Maximum efficacy
Week 12 Week 24 Week 28
255 45 mg 0, 4, q12w 67% 76% 71%
256 90 mg 0, 4, q12w 66% 85% 78%
255 Placebo 3%
Placebo randomized n = 123 45 mg week 12, 16, q12w 66%
n = 119 90 mg week 12, 16, q12w 85%
Phoenix II Primary endpoint
N Dosing Week PASI 75 response Maximum efficacy
Week 12 Week 20 Week 28
411 90 mg 0, 4, q12w 76% 84% 75%
410 Placebo 4%
Placebo randomized n = 193 45 mg week 12, 16, q12w 70%
n = 194 90 mg week 12, 16, q12w 79%
Notes: Phoenix i was designed in a three-way group 1:1:1 (ustekinumab 45, 90- and placebo with treatment at week 0, 4, and every 12 weeks) with primary endpoint 
evaluating PASi 75 response at week 12. At that point placebo group was randomized into two groups (ustekinumab 45 and 90 mg with treatment at week 12, 16, and every 
12 weeks). Therefore primary endpoint for the placebo randomized groups was at week 28. At week 28 in all three groups nonresponders (PASi ,50) were discontinued 
from study, partial responders (PASi 50 to ,75) began dosing every 8 weeks and PASi responders (.75) continued every 12 weeks. At week 40 patients from the responders 
groups were re-randomized to either placebo or continue every 12 weeks and patients from the placebo group who were randomized to treatment returned to placebo 
and at loss of therapeutic effect were started back on ustekinumab with the last dose they were receiving. At that point nonresponders or partial responders were given 
ustekinumab every 8 weeks until week 76 end of study. Phoenix ii was designed in the same way as Phoenix i but the only difference is that at week 28 partial responders 
were assigned to receive ustekinumab every 8 weeks and the study ended at week 52, the same nonresponders were discontinued from study.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Institute for Health and Clinical Excellence guidance issued 
as a result of the single technology appraisal process states 
that ustekinumab is recommended as a treatment option for 
adults with plaque psoriasis, but a number of criteria need 
to be met.58
The potential for infectious, malignant, metabolic, car-
diovascular, and paradoxical complications should always 
be considered, and further studies are needed to assess the 
role of ustekinumab in the treatment of other musculoskeletal 
and extra-articular clinical conditions and comorbidities.24 
However, it should be noted that ustekinumab has been 
shown to improve symptoms of anxiety, depression, and 
health-related quality of life significantly.59,60
Briakinumab (ABT-874) is another interleukin 12 and 
23 inhibitor which is currently in Phase III clinical trials. 
Its efficacy for moderate to severe psoriasis appears to be 
comparable with that of ustekinumab.61 An abstract recently 
presented to the American Academy of Dermatology showed 
that 11 major adverse cardiovascular events were observed 
during the open-label extension study, in addition to seven 
from one run-in study. Using a composite of four cardio-
vascular risk factors, a retrospective analysis revealed that 
major adverse cardiovascular events occurred at a rate of 
,0.3 events/100 patient-years in patients with one or fewer 
risk factors compared with .2.0 events/100 patient-years 
in those with two or more risk factors. It was concluded that 
this interim analysis supports the need to monitor closely 
for adverse events of infection, malignancies, and cardio-
vascular risk factors that may contribute to major adverse 
cardiovascular events in patients receiving briakinumab for 
the treatment of moderate to severe psoriasis.61
Of interest, a series of reports has shown that ustekinumab-
treated patients exhibit significant improvement in histo-
logical measures of psoriasis, with minimal impact on the 
systemic immune response.62 No changes in serum TNF-α 
concentrations were seen, or any significant variation in 
the percentages of cells expressing CD45RA, CD45RO, 
CD25, HLA-DR, and CXCR3 chemokine. In addition, no 
apparent effect on the magnitude of Th1/Th2 responses 
to external stimuli in peripheral blood mononuclear 
cells was observed following treatment with placebo or 
ustekinumab.62 Furthermore, administration of ustekinumab 
to both Cynomolgus monkeys and humans revealed that 
  treatment does not significantly impair recall immune system 
fu  nctions, or have adverse effects on prenatal or postnatal 
development.63,64
In conclusion, accumulating evidence supports the 
efficacy and safety of ustekinumab for the treatment of 
moderate to severe psoriasis. There is some suggestion from 
head-to-head comparisons that ustekinumab may offer some 
advantage over TNF-α inhibitors. However, there is a need 
for larger and longer-term studies to assess the safety profile, 
cost-effectiveness, and advantages of anti-interleukin 12 and 
23 activity in the modern era of biological therapy.65
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